Literature DB >> 26406416

Markers of progression and invasion in short term follow up of untreated breast cancer patients.

Zaki Abu Rabi, Nataša Todorović-Raković, Tijana Vujasinović, Jelena Milovanović, Dragica Nikolić-Vukosavljević.   

Abstract

BACKGROUND: Cancer progression and metastasis are complex processes, dependent of molecules involved in inflammation, degradation and invasion. These molecules can be used as prognostic indicators to single out patients with higher risk of recurrence. Interleukin-8 (IL-8) has a role in inflammation, urokinase plasminogen activator (uPA), plasminogen activator inhibitor type-1 (PAI-1) and matrix metalloproteinase-2, -9 have a decisive part in the process of degradation and invasion, while vascular endothelial growth factor (VEGF) is consequential for angiogenesis.
OBJECTIVES: Aim of our study is to determine relations between IL-8, uPA, PAI-1, MMP-2, -9, VEGF as their prognostic significance in terms of recurrence free survival.
METHODS: This study included 91 untreated patients with lymph node negative (N0) primary breast cancer.
RESULTS: Patients with higher levels of uPA (p= 0.05), PAI-1 (0.05), MMP2 (p= 0.05) and IL-8 (p= 0.02) have a poor prognosis. Positive correlations were found between ER - PR, uPA - PAI-1, uPA - MMP9, PAI-1 - IL-8, MMP9 - IL-8, MMP9 - VEGF. Negative correlations were found between ER - IL-8, uPA - IL-8, MMP2 - VEGF.
CONCLUSIONS: Higher concentrations of IL-8, uPA, PAI-1 and MMP2, as is MMP9 and VEGF, confirmed aggressive phenotype and poor prognosis in different subgroups.

Entities:  

Keywords:  Breast cancer; interleukin 8; lymph node; matrix metalloproteinase; plasminogen activator; prognostic markers; progression

Mesh:

Substances:

Year:  2015        PMID: 26406416     DOI: 10.3233/CBM-150516

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  8 in total

1.  Interleukin 8 in progression of hormone-dependent early breast cancer.

Authors:  Jelena Milovanovic; Natasa Todorovic-Rakovic; Tijana Vujasinovic; Zaki Abu Rabi
Journal:  J Biosci       Date:  2017-06       Impact factor: 1.826

2.  Unveiling a Hidden Biomarker of Inflammation and Tumor Progression: The 65 kDa Isoform of MMP-9 New Horizons for Therapy.

Authors:  Rocco Rossano; Marilena Larocca; Margherita Macellaro; Domenico Bilancia; Paolo Riccio
Journal:  Curr Issues Mol Biol       Date:  2021-12-25       Impact factor: 2.976

3.  Kaempferol Inhibits the Invasion and Migration of Renal Cancer Cells through the Downregulation of AKT and FAK Pathways.

Authors:  Tung-Wei Hung; Pei-Ni Chen; Hsu-Chen Wu; Sheng-Wen Wu; Pao-Yu Tsai; Yih-Shou Hsieh; Horng-Rong Chang
Journal:  Int J Med Sci       Date:  2017-08-18       Impact factor: 3.738

4.  Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients.

Authors:  Nina Fokter Dovnik; Iztok Takac
Journal:  Radiol Oncol       Date:  2016-05-09       Impact factor: 2.991

5.  Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array.

Authors:  Hans-Ullrich Völker; Michael Weigel; Annette Strehl; Lea Frey
Journal:  Diagn Pathol       Date:  2018-08-31       Impact factor: 2.644

Review 6.  miR-615 Fine-Tunes Growth and Development and Has a Role in Cancer and in Neural Repair.

Authors:  Marisol Godínez-Rubí; Daniel Ortuño-Sahagún
Journal:  Cells       Date:  2020-06-27       Impact factor: 6.600

7.  Loss of Kaiso expression in breast cancer cells prevents intra-vascular invasion in the lung and secondary metastasis.

Authors:  Jacek M Kwiecien; Blessing I Bassey-Archibong; Wojciech Dabrowski; Lyndsay G Rayner; Alexandra R Lucas; Juliet M Daniel
Journal:  PLoS One       Date:  2017-09-07       Impact factor: 3.240

8.  Biomarkers of tumor invasiveness in proteomics (Review).

Authors:  Daniel L Pouliquen; Alice Boissard; Olivier Coqueret; Catherine Guette
Journal:  Int J Oncol       Date:  2020-05-28       Impact factor: 5.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.